Aquestive Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AQST and other ETFs, options, and stocks.

About AQST

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. 

CEO
Daniel Barber
CEODaniel Barber
Employees
142
Employees142
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
2004
Founded2004
Employees
142
Employees142

AQST Key Statistics

Market cap
468.49M
Market cap468.49M
Price-Earnings ratio
-5.46
Price-Earnings ratio-5.46
Dividend yield
Dividend yield
Average volume
9.85M
Average volume9.85M
High today
$4.03
High today$4.03
Low today
$3.76
Low today$3.76
Open price
$3.91
Open price$3.91
Volume
3.97M
Volume3.97M
52 Week high
$7.55
52 Week high$7.55
52 Week low
$2.12
52 Week low$2.12

Stock Snapshot

As of today, Aquestive Therapeutics(AQST) shares are valued at $3.77. The company's market cap stands at 468.49M, with a P/E ratio of -5.46.

On 2026-02-06, Aquestive Therapeutics(AQST) stock moved within a range of $3.76 to $4.03. With shares now at $3.77, the stock is trading +0.4% above its intraday low and -6.3% below the session's peak.

Trading volume for Aquestive Therapeutics(AQST) stock has reached 3.97M, versus its average volume of 9.85M.

Over the past 52 weeks, Aquestive Therapeutics(AQST) stock has traded between a high of $7.55 and a low of $2.12.

Over the past 52 weeks, Aquestive Therapeutics(AQST) stock has traded between a high of $7.55 and a low of $2.12.

AQST News

Simply Wall St 2d
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. Estimates For 2026

One thing we could say about the analysts on Aquestive Therapeutics, Inc. ( ) - they aren't optimistic, having just made a major negative revision to their near...

Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. Estimates For 2026
Simply Wall St 3d
Assessing Aquestive Therapeutics Valuation After The FDA Complete Response Letter For Anaphylm

Advertisement Why the FDA’s Complete Response Letter Matters for Aquestive Aquestive Therapeutics (AQST) has drawn fresh attention after the FDA issued a Comp...

Assessing Aquestive Therapeutics Valuation After The FDA Complete Response Letter For Anaphylm
Nasdaq 4d
Aquestive Therapeutics Stock Surges 43% Over Complete Response Letter From FDA For Anaphylm NDA

(RTTNews) - Stock of Aquestive Therapeutics, Inc. (AQST) is soaring about 43 percent on Monday morning trading following its announcement about a Complete Respo...

Aquestive Therapeutics Stock Surges 43% Over Complete Response Letter From FDA For Anaphylm NDA

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More AQST News

TipRanks 4d
Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

Aquestive Therapeutics (AQST) announced that it received a Complete Response Letter, CRL, from the U.S. Food and Drug Administration, FDA, on January 30, 2026 f...

People also own

Based on the portfolios of people who own AQST. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.